Skip to content
HowShorted

Corbus Pharmaceuticals Holdings, Inc. short interest in 2022

In 2022, Corbus Pharmaceuticals Holdings, Inc.'s disclosed short interest ran from 4.14% of shares outstanding on 14 Jan 2022 to 2.93% on 30 Dec 2022, a change of -1.21 percentage points. The year's high was 4.14% on 14 Jan 2022 and its low 2.60% on 29 Jul 2022, averaging 3.25% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.17 days on 29 Jul 2022. Full history: Corbus Pharmaceuticals Holdings, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Corbus Pharmaceuticals Holdings, Inc. in 2022

2022 in figures

Start of year
4.14% (14 Jan 2022)
End of year
2.93% (30 Dec 2022)
Change
-1.21 pp
High
4.14% (14 Jan 2022)
Low
2.60% (29 Jul 2022)
Average
3.25%
Highest days to cover
9.17 (29 Jul 2022)
SEC filings marked
8

Every report in 2022

Corbus Pharmaceuticals Holdings, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20224.14%6.87
31 Jan 20223.91%5.36
15 Feb 20223.85%2.32
28 Feb 20223.56%4.73
15 Mar 20223.59%4.7210-K filed, results (8-K)
31 Mar 20223.57%2.29
14 Apr 20223.37%5.76
29 Apr 20223.07%8.17
13 May 20223.26%3.4210-Q filed, results (8-K)
31 May 20222.81%1.00
15 Jun 20222.80%5.41
30 Jun 20222.66%4.82
15 Jul 20222.62%4.99
29 Jul 20222.60%9.17
15 Aug 20223.08%4.0610-Q filed, results (8-K)
31 Aug 20223.03%2.23
15 Sep 20222.68%6.01
30 Sep 20222.97%3.06
14 Oct 20223.12%1.00
31 Oct 20223.80%1.00
15 Nov 20223.70%3.6110-Q filed
30 Nov 20223.15%1.00
15 Dec 20223.70%1.12
30 Dec 20222.93%2.66results (8-K)

See also: Corbus Pharmaceuticals Holdings, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.